A League of Its Own? Established and Emerging Therapies in Undifferentiated Pleomorphic Sarcoma

被引:0
作者
Laurie Graves
William R. Jeck
Juneko E. Grilley-Olson
机构
[1] Duke University,Division of Pediatric Hematology & Oncology
[2] Duke University,Department of Pathology
[3] Duke Cancer Institute,Division of Medical Oncology
[4] Duke University,undefined
来源
Current Treatment Options in Oncology | 2023年 / 24卷
关键词
Undifferentiated pleomorphic sarcoma; Soft tissue sarcoma; Chemotherapy; Systemic therapy; Checkpoint inhibition; Immunotherapy;
D O I
暂无
中图分类号
学科分类号
摘要
Over the last decade in soft tissue sarcoma (STS) research, the shifting landscape towards more precise subtype classification and the increasing study of novel therapeutic strategies has prompted a need to highlight current knowledge of effective subtype specific therapies. Undifferentiated pleomorphic sarcoma (UPS), formerly known as malignant fibrous histiocytoma (MFH), is among the most common subtypes of STS arising in the trunk or extremities of adults. Administration of systemic chemotherapy is the primary management in locally advanced and metastatic UPS. While anthracycline-based chemotherapy continues to be standard of care in this setting, outcomes in locally advanced or metastatic UPS remain poor. Recent studies highlight the unique characteristics of UPS that may contribute to its greater sensitivity to immune checkpoint inhibition (ICI) compared to other STS subtypes. With the promise of benefit from novel therapies, including ICI or ICI plus chemotherapy, for a subset of patients with UPS comes the need to identify biomarkers predictive of response to therapy. Ongoing and future clinical trials should place strong emphasis on correlative biomarker studies to learn more about the unique biology of UPS and to identify patients for whom ICI-based therapy will be effective.
引用
收藏
页码:212 / 228
页数:16
相关论文
共 272 条
[1]  
Crago AM(2022)Management of myxofibrosarcoma and undifferentiated pleomorphic sarcoma Surg Oncol Clin N Am. 31 419-430
[2]  
Cardona K(2014)Lessons learned from the study of 10,000 patients with soft tissue sarcoma Ann Surg 260 416-421
[3]  
Koseła-Paterczyk H(2018)Presentation and outcome of frequent and rare sarcoma histologic subtypes: a study of 10,262 patients with localized visceral/soft tissue sarcoma managed in reference centers Cancer 124 1179-1187
[4]  
Rutkowski P(2015)MFH and high-grade undifferentiated pleomorphic sarcoma-what’s in a name? J Surg Oncol. 111 173-177
[5]  
Brennan MF(2014)Sarcoma classification: an update based on the 2013 World Health Organization Classification of Tumors of Soft Tissue and Bone Cancer. 120 1763-1774
[6]  
Antonescu CR(2021)The 2020 WHO Classification of Tumors of Soft Tissue: selected changes and new entities Adv Anat Pathol. 28 44-58
[7]  
Moraco N(1964)Malignant fibrous xanthomas Cancer 17 1445-1456
[8]  
Singer S(1978)Malignant fibrous histiocytoma: an analysis of 200 cases Cancer. 41 2250-2266
[9]  
Penel N(1977)Myxoid variant of malignant fibrous histiocytoma Cancer. 39 1672-1685
[10]  
Coindre J-M(1992)Pleomorphic malignant fibrous histiocytoma: fact or fiction? A critical reappraisal based on 159 tumors diagnosed as pleomorphic sarcoma Am J Surg Pathol. 16 213-228